A Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment (PVD)

Bausch + Lomb

Status and phase: Terminated; Phase 2; Phase 1

Conditions: Vitreoretinal Traction Syndrome

Treatments: Drug: Plasmin

Study type: Interventional

Funder types: Industry

Identifiers

NCT00347646

484

Details and patient eligibility

About

Plasmin is expected to create a posterior vitreous detachment (PVD) when injected directly into the eye. The pharmacological creation of a PVD may be beneficial in helping to treat a variety of conditions.

Enrollment: 4 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who are in need of a vitrectomy.

Exclusion criteria

• A PVD in the study eye as assessed by the investigator using ophthalmic and alternative examination techniques.
• A history of vitrectomy in the study eye.
• A media opacity that precludes quality examination of the vitreous and fundus in the study eye.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

4 participants in 1 patient group

Plasmin

Experimental group

Description:

Human-derived plasmin reconstituted with sterile sodium chloride for intravitreal injection.

Treatment:

Drug: Plasmin